Vadodara-based Alembic Pharmaceuticals Limited on Tuesday announced a joint venture (JV) for entering the Chinese market, the world’s second largest single country drug market after the US. The $100 bn Chinese market, estimated to be tough to crack, has recently shown signs of easing regulatory norms to encourage generic players to enter. Alembic Pharma has signed a JV with SPH SINE Pharmaceutical Laboratories Co Ltd, China (SPH Sine) & Adia (Shanghai) Pharma Co Ltd, China (Adia) for promotion and sales of its pharmaceutical products in the Chinese market.
Alembic Pharma forms JV to enter a difficult $100 bn Chinese market
Date posted: Wednesday 8 May 2019